Can Allergan Remain Independent of Valeant?

Good earnings don't make a strong enough case for Allergan to stay independent

May 8, 2014 at 6:30PM

Thanks to the now-public interest of Valeant (NYSE:VRX) in making Allergan (NYSE:AGN) its own, not to mention the vocal and financial support of Pershing Square and Bill Ackman, the status quo is gone for good at Allergan. Good first quarter results and improved guidance for the year were both nice to see, but Allergan is going to have to do a lot more to convince its shareholders that a plan for the future that excludes selling out to Valeant has their best interests at heart.

Good results help a little
I suppose Valeant would be able to crow a little louder about the need for sweeping cost cuts if Allergan had posted an expense-driven miss, but first quarter results were pretty good.

Revenue rose 13% as reported, good for a modest beat versus sell-side expectations. Allergan's outperformance was spread fairly evenly across the business, as pharmaceutical revenue rose 10% on 9% growth in eye care, 10% growth in Botox (slightly weak), and 10% growth in skin care. Devices were up 23%, with 11% growth in breast implants and 33% growth in facial aesthetics.

Allergan extended its outperformance down the income statement. Gross margin improved more than half a point from last year, beating expectations for flat performance. Operating income rose 31%, beating expectations by 6% as the company slightly underspent expectations as a percentage of sales.

And now what?
While Valeant has been trying to drum up shareholder support for its bid for Allergan, the target has been relatively quiet beyond its initial rejection and poison pill efforts. Rumors are flying all over the place that Allergan is beating the bushes, looking for either a target of its own or a "white knight" bidder that would acquire the company without the slash-and-burn cost cuts proposed by Valeant.

A key focus of these discussions has been Shire (NASDAQ:SHPG). Several sources, led I believe by Reuters, have reported that Allergan approached Shire earlier this year regarding a merger/acquisition.

Shire would hold some obvious appeal. Acquiring Shire would facilitate a tax inversion that would lower Allergan's income tax rate (a key benefit of the Valeant offer) and as both companies have sizable SG&A and R&D spends, there could be some real cost-cutting opportunities here (however ironic that may be). There are also good top-line reasons for a deal – Shire would complement Allergan's ophthalmology business and its rare disease drug business would generate the sort of above-average growth that Allergan needs to sell any alternative proposals to its shareholders.

Other acquisition targets for Allergan could include Teva or Alkermes, with Merck KGaA and UCB as even bigger longshots.

Will a white knight show up?
If Allergan cannot swallow another company and make itself indigestible to Valeant in the process, it may be possible to find an alternative bidder – one that would preserve more of the company, it's R&D, and its employees' jobs. Given the advantages that Valeant stands to reap, though, it's going to be hard to find a superior deal.

Perhaps Pfizer would be interested if it couldn't consummate its bid for AstraZeneca, as Allergan would offer some modest synergies in dermatology and Allergan's products could be leveraged through Pfizer's global sales force. I continue to believe, though, that Johnson & Johnson and AstraZeneca would be more probable alternative bidders, though I'd hardly describe either company's involvement as "likely".

The bottom line
Allergan's near-term financial performance is almost trivial in the context of its value today. The dominant question now is whether Allergan can find an acquisition of its own, an alternative bidder, or secure a higher price from Valeant. Much as Allergan may not like Valeant or its proposed changes to Allergan's business, management has an obligation to do right by shareholders (the owners of the company). Unless Allergan can court Shire on attractive terms, swallowing hard and extracting more from Valeant may be the best option left on the table.

Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson, Valeant Pharmaceuticals, and Teva Pharmaceutical Industries. The Motley Fool owns shares of Johnson & Johnson and Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers